



INLAND EMPIRE HEALTH PLAN

**IEHP UM Subcommittee Approved Authorizations Guidelines**  
***Bone Marrow Transplant in the Treatment of Multiple Sclerosis***

**Policy:**

On January 26, 2006, the UM Subcommittee determined that Bone Marrow Transplant in the Treatment of Multiple Sclerosis is investigational and not of proven value. The UM Subcommittee's recommendation is to not cover this procedure at this time. Upon review in 2016, the guidelines remain unchanged.

## Carrier Statements:

Bone Marrow Transplant for the treatment of Multiple Sclerosis is not currently reimbursed by Aetna, Cigna, Medical or Medicare.

**Effective Date:** *January 26, 2008***Reviewed Annually:** *December 17, 2020***Revised:**

May 11, 2016

**Bibliography:**

**ECHRI Institute. (2015). Horizon Scanning Status Update: September 2015. AHRQ Healthcare Horizon Scanning System - Status Updates.**

**ECHRI Institute. (2009). Evidence Report: Immunoablative Therapy with Bone Marrow or Peripheral Stem Cell Transplantation for Multiple Sclerosis. Health Technology Assessment Information Service.**  
**Aetna. (2015, October 23). Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications. Retrieved March 25, 2016, from [http://www.aetna.com/cpb/medical/data/600\\_699/0606.html](http://www.aetna.com/cpb/medical/data/600_699/0606.html)**  
**Policy number 0606**

**Cigna. (2015, July 15). Cigna Medical Coverage Policy: Stem cell transplant for Autoimmune Diseases. Coverage Policy Number: 0357. Retrieved March 25, 2016, from [https://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/medical/mm\\_0357\\_coveragepositioncriteri\\_a\\_stem\\_cell\\_transplant\\_autoimmune\\_diseases.pdf](https://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/medical/mm_0357_coveragepositioncriteri_a_stem_cell_transplant_autoimmune_diseases.pdf)**

10801 Sixth St, Suite 120, Rancho Cucamonga, CA 91730  
 Tel (909) 890-2000 Fax (909) 890-2003  
 Visit our web site at: [www.iehp.org](http://www.iehp.org)

*A Public Entity*

**Majhail, N. S., Farnia, S. H., Carpenter, P. A., Champlin, R. E., Crawford, S., Marks, D. I., . . . Lemaistre, C. F. (2015). Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, 21(11), 1863-1869.**

**Radaelli, M., Merlini, A., Greco, R., Sangalli, F., Comi, G., Ciceri, F., & Martino, G. (2014). Autologous Bone Marrow Transplantation for the Treatment of Multiple Sclerosis. *Current Neurology and Neuroscience Reports Curr Neurol Neurosci Rep*, 14(9).**

**Rice, C. M., Kemp, K., Wilkins, A., & Scolding, N. J. (2013). Cell therapy for multiple sclerosis: An evolving concept with implications for other neurodegenerative diseases. *The Lancet*, 382(9899), 1204-1213.**

**Rodrigues, M. C., Hamerschlak, N., Moraes, D. A., Simões, B. P., Rodrigues, M., Ribeiro, A. A., & Voltarelli, J. C. (2013). Guidelines of the Brazilian Society of Bone Marrow Transplantation on hematopoietic stem cell transplantation as a treatment for the autoimmune diseases systemic sclerosis and multiple sclerosis. *Revista Brasileira De Hematologia E Hemoterapia*, 35(2).**

### **Disclaimer**

IEHP Clinical Authorization Guidelines (CAG) are developed to assist in administering plan benefits, they do not constitute a description of plan benefits. The Clinical Authorization Guidelines (CAG) express IEHP's determination of whether certain services or supplies are medically necessary, experimental and investigational, or cosmetic. IEHP has reached these conclusions based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). IEHP makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in the Clinical Authorization Guidelines (CAG). IEHP expressly and solely reserves the right to revise the Clinical Authorization Guidelines (CAG), as clinical information changes.